CenterBook Partners’s Xeris Biopharma Holdings XERS Stock Holding History

CenterBook Partners’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Sell	280,565 -968,056	-78%	-$6.18M	0.11%	210
2026 Q1	$7.24M	Sell	1,248,621 -142,969	-10%	-$948K	0.39%	63
2025 Q4	$10.9M	Buy	1,391,590 +693,386	+99%	+$5.46M	0.53%	37
2025 Q3	$5.68M	Sell	698,204 -896,025	-56%	-$5.95M	0.28%	88
2025 Q2	$7.45M	Buy	1,594,229 +1,122,154	+238%	+$5.14M	0.41%	53
2025 Q1	$2.59M	Sell	472,075 -218,002	-32%	-$880K	0.17%	159
2024 Q4	$2.34M	Sell	690,077 -2,791,929	-80%	-$8.98M	0.14%	186
2024 Q3	$9.92M	Buy	3,482,006 +2,016,131	+138%	+$5.18M	0.61%	37
2024 Q2	$3.3M	Sell	1,465,875 -77,998	-5%	-$157K	0.21%	189
2024 Q1	$3.41M	Buy	1,543,873 +1,433,246	+1,296%	+$3.71M	0.24%	164
2023 Q4	$260K	Buy	+110,627	New	+$204K	0.03%	367

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CenterBook Partners's XERS Position: Q2 2026 in Review

CenterBook Partners reduced its Xeris Biopharma Holdings (XERS) stake by 78% in Q2 2026, selling an estimated $6.18M and leaving 280,565 shares worth $2.22M. The position accounts for 0.11% of the portfolio, ranked #210.

CenterBook Partners first reported a position in XERS in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.9M in Q4 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

CenterBook Partners held 280,565 shares of Xeris Biopharma Holdings worth $2.22M as of Q2 2026.
CenterBook Partners sold 968,056 Xeris Biopharma Holdings shares in Q2 2026, an estimated $6.18M.
Xeris Biopharma Holdings made up 0.11% of CenterBook Partners's portfolio in Q2 2026, its #210 holding.
CenterBook Partners first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 11 quarters since.
CenterBook Partners's Xeris Biopharma Holdings position peaked at $10.9M in Q4 2025.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.